These Case-Based Roundtable article and video series explore recent perspectives on treatment strategies around clinical case profiles.
Therapeutic Choices for Patients With HR-Positive, HER2-Low Breast Cancer
March 15th 2024This Evolving Paradigm Roundtable reviews the later-line options for patients with hormone receptor–positive, HER2-low or -negative inoperable or metastatic breast cancer, as discussed by key opinion leaders and participants at virtual live events.
Treatment Options in Patients With R/R Multiple Myeloma in the Later-Line Setting
September 27th 2023This roundtable series evaluates therapies for patients with relapsed/refractory multiple myeloma after they have recieved multiple types of treatment, as discussed by key opinion leaders and participants at virtual live events.
Therapeutic Choices in dMMR Recurrent or Advanced Endometrial Cancer
August 10th 2023This roundtable series reviews options after progression on platinum-regimens for patients with mismatch repair–deficient recurrent or advanced endometrial cancer, as discussed by key opinion leaders and participants at virtual live events.
Treating Patients With Metastatic or Recurrent Cervical Cancer Post Chemotherapy
July 27th 2023This roundtable series discusses antibody-drug conjugates as therapy for patients with cervical cancer who had progressed on chemotherapy, as discussed by key opinion leaders and participants at virtual live events.
Options Post First-Line Progression in mCRPC With HRR Mutations
May 22nd 2023This roundtable series assesses treatment after first-line progression for patients with deleterious germline or somatic homologous recombination repair-mutated metastatic castration-resistant prostate cancer, as discussed by key opinion leaders and participants at virtual live events.
Patients With Advanced Hodgkin Lymphoma Treated Using Frontline Immunotherapy Plus Chemotherapy
March 29th 2023This roundtable series evaluates the use of combination therapies using immunotherapy and chemotherapy in patients with advanced Hodgkin lymphoma, as discussed by key opinion leaders and participants at virtual live events.
Therapeutic Options for Patients With Multiple Myeloma in the Second Line and Beyond
March 20th 2023This roundtable series reviews treatments in adult patients with multiple myeloma who have progressed on 1 or more lines of therapy, as discussed by key opinion leaders and participants at virtual live events.
Treating Patients With Breast Cancer After Progression on Endocrine Therapy
March 17th 2023This roundtable series explores therapies after progression on endocrine therapy in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer who have an ESR1 mutation,as discussed by key opinion leaders and participants at virtual live events.
Later-Line Combination Therapies Used as Treatment in Multiple Myeloma
March 13th 2023This roundtable series considers the use of combination treatments in patients with relapsed/refractory multiple myeloma who have received 2 or more lines of therapy, as discussed by key opinion leaders and participants at virtual live events.
How to Recognize, Diagnose, and Treat Patients With BPDCN
September 28th 2022This roundtable series discusses blastic plasmacytoid dendritic cell neoplasms in patients and the ways to identify and provide therapy for this rare disease, as discussed by key opinion leaders and participants at virtual live events.
Sequencing for Metastatic Clear Cell Renal Cell Carcinoma After Prior Therapy
September 16th 2022This roundtable series considers multiple therapies from published clinical trials for patients with relapsed/refractory metastatic clear cell renal cell carcinoma, as discussed by key opinion leaders and participants at virtual live events.
Management and Treatment of Patients With Exon 20 Non–Small Cell Lung Cancer
September 14th 2022This roundtable series reviews molecular testing in non–small cell lung cancer and potential treatments for patients with EGFR exon 20 mutations, as discussed by key opinion leaders and participants at virtual live events.
Experts Discuss the RCC Landscape and Available Therapy for Patients
September 13th 2022This roundtable series provides insights on assessing patients with renal cell carcinoma and how to treat them in the first line based on their risk factors, as discussed by experts in video interviews with Targeted Oncology.
Later-Line Options for Patients With PSMA-Positive mCRPC
July 25th 2022This roundtable series evaluates radioligand therapy in patients with previously treated metastatic castration-resistant prostate cancer with positive prostate-specific membrane antigen, as discussed by participants at virtual live events.
DLBCL Management With Combination Therapy in the Relapsed/Refractory Setting
July 6th 2022This roundtable series assesses the use of antibody-drug conjugates plus chemoimmunotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma setting, as discussed by participants at virtual live events.